Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice

Zhang, Qing; Li, Qihong; Zhu, Jun; Guo, Hao; Zhai, Qiming; Li, Bei; Jin, Yan; He, Xiaoning; Jin, Fang

doi:10.7717/peerj.7023

Cited by 43 publications

(42 citation statements)

References 56 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, BMSCs also applied to treat chronic inflammatory diseases [136,137]. A comparative study showed that the systemic infusion of BMSCs significantly improved symptoms of RA in mice [138]. BMSCs reduced bone erosions, synovitis and articular destruction, levels of TNF-α and IL-1β in serum and joint, which results in an improvement of inflammation state in RA mice.…”

Section: Bmscs Involved In the Treatment Of Immune Disorder Diseasesmentioning

confidence: 99%

“…BMSCs reduced bone erosions, synovitis and articular destruction, levels of TNF-α and IL-1β in serum and joint, which results in an improvement of inflammation state in RA mice. BMSCs are considered to be the best stem cells for the treatment of RA when compared to UCSCs and exfoliated deciduous teeth stem cells [138]. In addition, a randomized, triple-blind trial showed the improvement of Western Ontario and McMaster Universities Arthritis Index (WOMAC), visual analog scale (VAS), time to jelling, pain-free walking distance, and standing time in 30 RA patients treated with BMSCs [139].…”

Section: Bmscs Involved In the Treatment Of Immune Disorder Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Chu

Phuong

Tien

et al. 2020

IJMS

123

View full text Add to dashboard Cite

Bone marrow mesenchymal stem/stromal cells (BMSCs), which are known as multipotent cells, are widely used in the treatment of various diseases via their self-renewable, differentiation, and immunomodulatory properties. In-vitro and in-vivo studies have supported the understanding mechanisms, safety, and efficacy of BMSCs therapy in clinical applications. The number of clinical trials in phase I/II is accelerating; however, they are limited in the size of subjects, regulations, and standards for the preparation and transportation and administration of BMSCs, leading to inconsistency in the input and outcome of the therapy. Based on the International Society for Cellular Therapy guidelines, the characterization, isolation, cultivation, differentiation, and applications can be optimized and standardized, which are compliant with good manufacturing practice requirements to produce clinical-grade preparation of BMSCs. This review highlights and updates on the progress of production, as well as provides further challenges in the studies of BMSCs, for the approval of BMSCs widely in clinical application.

show abstract

Section: Bmscs Involved In the Treatment Of Immune Disorder Diseasesmentioning

confidence: 99%

Section: Bmscs Involved In the Treatment Of Immune Disorder Diseasesmentioning

confidence: 99%

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Chu

Phuong

Tien

et al. 2020

IJMS

123

View full text Add to dashboard Cite

show abstract

“…By far, the most prevalent source of MSCs is adult bone marrow (BM), followed by adipose tissue and, more recently, umbilical cord either from whole tissue or more specifically from umbilical cord blood (UC) [ 48 , 49 , 50 ]. Of late, MSCs have been isolated from alternative tissues [ 51 ], such as gingiva [ 52 , 53 ], amniotic fluid [ 54 , 55 ], placenta [ 56 ], synovial fluid or membrane [ 57 ], and nasal tissues ( ; patent number: WO2019022386, [ 58 , 59 ]). In all instances, the expanded MSCs matched with the minimal criteria defined by the International Society for Cellular Therapy (ISCT) [ 60 ] and have demonstrated similar efficacy in ameliorating experimental arthritis [ 47 ].…”

Section: Preclinical Studiesmentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications

López‐Santalla

Fernandez-Perez

Garín

2020

Cells

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects the lining of the synovial joints leading to stiffness, pain, inflammation, loss of mobility, and erosion of joints. Its pathogenesis is related to aberrant immune responses against the synovium. Dysfunction of innate and adaptive immunity, including dysregulated cytokine networks and immune complex-mediated complement activation, are involved in the progression of RA. At present, drug treatments, including corticosteroids, antirheumatic drugs, and biological agents, are used in order to modulate the altered immune responses. Chronic use of these drugs may cause adverse effects to a significant number of RA patients. Additionally, some RA patients are resistant to these therapies. In recent years, mesenchymal stem/stromal cell (MSCs)-based therapies have been largely proposed as a novel and promising stem cell therapeutic approach in the treatment of RA. MSCs are multipotent progenitor cells that have immunomodulatory properties and can be obtained and expanded easily. Today, nearly one hundred studies in preclinical models of RA have shown promising trends for clinical application. Proof-of-concept clinical studies have demonstrated satisfactory safety profile of MSC therapy in RA patients. The present review discusses MSC-based therapy approaches with a focus on published clinical data, as well as on clinical trials, for treatment of RA that are currently underway.

show abstract

“…An in vivo study indicated that treatment with MSCs obtained from different sources (bone marrow, umbilical cord, or human exfoliated deciduous teeth) in a mouse model of collagen-induced arthritis significantly improved bone erosions, synovitis, and articular destruction [304]. This improvement of clinical symptoms was paralleled by reduced levels of the pro-inflammatory cytokines TNF-α and IL-1β both in serum and joints [304].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis

Lin

Anzaghe

Schülke

2020

Cells

534

376

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease that involves multiple joints bilaterally. It is characterized by an inflammation of the tendon (tenosynovitis) resulting in both cartilage destruction and bone erosion. While until the 1990s RA frequently resulted in disability, inability to work, and increased mortality, newer treatment options have made RA a manageable disease. Here, great progress has been made in the development of disease-modifying anti-rheumatic drugs (DMARDs) which target inflammation and thereby prevent further joint damage. The available DMARDs are subdivided into (1) conventional synthetic DMARDs (methotrexate, hydrochloroquine, and sulfadiazine), (2) targeted synthetic DMARDs (pan-JAK- and JAK1/2-inhibitors), and (3) biologic DMARDs (tumor necrosis factor (TNF)-α inhibitors, TNF-receptor (R) inhibitors, IL-6 inhibitors, IL-6R inhibitors, B cell depleting antibodies, and inhibitors of co-stimulatory molecules). While DMARDs have repeatedly demonstrated the potential to greatly improve disease symptoms and prevent disease progression in RA patients, they are associated with considerable side-effects and high financial costs. This review summarizes our current understanding of the underlying pathomechanism, diagnosis of RA, as well as the mode of action, clinical benefits, and side-effects of the currently available DMARDs.

show abstract

Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice

Cited by 43 publications

References 56 publications

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells

Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis

Contact Info

Product

Resources

About